



## 2005 Life Sciences

Life sciences leaders turn to WilmerHale for legal advice and business advantage. We provide incisive solutions to the business challenges facing biotechnology, pharmaceutical, healthcare and medical device companies at all stages of growth. For over four decades, we have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, licensing agreements and landmark collaborations, and have defended their innovations in critical patent litigation.

# Counsel of Choice to Life Sciences Leaders...from Biotech to Medical Devices.

## Venture Capital and PIPEs Financings

				
\$11,000,000 Third Round September 2005	\$15,000,000 Third Round May 2005	\$13,000,000 First Round February 2005	\$15,000,000 Fourth Round April 2005	
				
\$54,500,000 PIPEs Financing June 2005	\$42,000,000 Third Round October 2005	\$20,000,000 Second Round March 2005	\$26,600,000 Late Stage September 2005	\$59,800,000 Second Round May 2005

## Public Offerings and Rule 144A Placements

					
Public Offering of Common Stock \$192,722,000 Counsel to Issuer October 2005	Rule 144A Placement of 5% Senior Notes due 2015 \$250,000,000 Counsel to Issuer May 2005	Initial Public Offering of Common Stock \$86,250,000 Counsel to Issuer December 2005	Public Offering of Common Stock \$29,000,000 Counsel to Issuer December 2005	Public Offerings of Common Stock \$126,322,500 Counsel to Underwriters April, June and September 2005	
					
Public Offering of Common Stock \$130,434,000 Counsel to Issuer July 2005	Public Offering of Common Stock \$84,318,000 Counsel to Underwriters February 2005	Initial Public Offering of Common Stock \$40,000,000 Counsel to Issuer February 2005	Public Offering of Common Stock \$49,335,000 Counsel to Underwriters October 2005	Rule 144A Placement of 1.50% Convertible Notes due 2012 \$200,000,000 Counsel to Issuer January 2005	Initial Public Offering of Common Stock \$63,250,000 Counsel to Issuer November 2005

## Strategic Alliances and Collaborations

					
Diabetes research and development agreement with Plurion	Alliance with Boston Scientific to develop products for diagnosing and treating neurological diseases	Alliance with Novartis for RNA interference therapeutics	Licensing advice for discovery research agreements	Anti-angiogenesis collaboration with Bausch & Lomb in ophthalmology	Collaboration with Schering-Plough for Integrilin® heart disease drug in the US
					
Collaboration with Novartis to develop immune modulatory compound therapeutics	Collaboration with ICOS Corporation for the joint development of therapeutic antibodies for cancer	Genetic profiling collaboration with Merck for targeted cancer drugs	Manufacturing and supply agreement with Schwarz Pharma Manufacturing	Collaboration with Alkermes for Vivitrol™ alcohol dependence drug in the US	

## Mergers and Acquisitions

			
acquisition by IMS Health Undisclosed July 2005	sale of global biologics manufacturing business to Ferring \$80,000,000 July 2005	acquisition by Shire Pharmaceuticals \$1,600,000,000 July 2005	acquisition by Clinical Data, Inc. \$56,000,000 October 2005
			
acquisition by OSI Pharmaceuticals \$935,000,000 November 2005	acquisition of Kendro Laboratory Products \$833,500,000 May 2005	acquisition by GE Healthcare \$1,200,000,000 January 2006	

